Figure 3.

Predicted (adjusted) 12-month COPD-related health care costs (in 2009 $US) associated with different initial maintenance therapies (data from the “cost population”).^a A) COPD-related health care costs; B) Breakdown of the medical component of COPD-related health care costs.

Note: ^aCosts were adjusted for age, gender, treatment, and comorbidities and COPD-related health care utilization at baseline. P-values are for differences between tiotropium and FSC, and between ipratropium and FSC.

Abbreviations: COPD, chronic obstructive pulmonary disease; FSC, fluticasone propionate/salmeterol combination.